Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce.

The European Medicines Agency (EMA) has recommended that marketing authorisation for Tavneos (avacopan) be revoked due to a question mark over the integrity of clinical data used to support its ...

Sobi has received a CRL from the US FDA regarding its BLA for NASP, an investigational therapy intended for adults with uncontrolled gout.

Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.